The following discussion contains forward-looking statements, which involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part II, Item 1A, "Risk Factors." The interim financial statements and this Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2008 and the related Management's Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2008. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.

Overview

Background

We are a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Our lead combination product candidates targeted for obesity are Contrave®, which has completed Phase 3 clinical trials, and Empatic™, which has completed Phase 2 clinical trials. Each of these product candidates is a combination of generic drugs, which we have systematically screened for synergistic central nervous system activity. Each of the components of our product candidates has already received regulatory approval and has been commercialized previously. In July 2009, we announced the results of the remaining Phase 3 clinical trials for Contrave. We expect to submit a new drug application, or NDA, with the U.S. Food and Drug Administration, or FDA, for Contrave in the first half of 2010. In September 2009, we announced the results of the latest Phase 2b clinical trial for Empatic. We plan to meet with the FDA for an End of Phase 2 meeting to discuss the results from our two Phase 2b trials with a goal of defining a Phase 3 plan for Empatic. We have not yet received regulatory approval for any product candidate.

We are a development stage company. We have incurred significant net losses since our inception. As of September 30, 2009, we had an accumulated deficit of $251.7 million. These losses have resulted principally from costs incurred in connection with research and development activities, primarily costs of clinical trial activities associated with our current product candidates, and general and administrative expenses. We expect to continue to incur operating losses for the next several years as we pursue the clinical development and market launch of our product candidates and acquire or in-license additional products and technologies, and add the necessary infrastructure to support our growth.

In July 2009, we completed a public offering of 11,500,000 shares of our common stock at a public offering price of $7.50 per share. Net cash proceeds from the public offering were $81.6 million, after deducting underwriting discounts, commissions and offering expenses.

Revenues

We have generated approximately $593,000 in revenue from inception through September 30, 2009, resulting from the sublicensing of technology and amounts earned under a collaborative agreement. During 2005, we sublicensed technology to Cypress Bioscience, Inc., or Cypress, for an upfront payment of $1.5 million, and this amount is being recognized ratably over the estimated life of the sublicensed patent. In addition, we recognized revenue of approximately $174,000 during the year ended December 31, 2005 related to a collaborative agreement with Eli Lilly and Company, or Eli Lilly, the term of which has since expired. We do not expect to generate any significant revenues from licensing, achievement of milestones or product sales unless and until we are able to obtain regulatory approval of, and commercialize, our product candidates either ourselves or with a collaborator. However, we may never generate revenues from our product candidates as we may never succeed in obtaining regulatory approval or commercializing products.

Research and Development Expenses

The majority of our operating expenses to date have been incurred in research and development activities. Our research and development expenses consist primarily of costs associated with clinical trials managed by our contract research organizations, or CROs, product development efforts and manufacturing costs. License fees, salaries and related employee benefits for certain personnel, and costs associated with certain non-clinical activities such as regulatory expenses, are also included in this amount. Our most significant costs to date are expenses incurred in connection with the clinical trials for Contrave and Empatic. The clinical trial expenses include payments to vendors such as CROs, investigators, suppliers of clinical drug materials and related consultants. We charge all research and development expenses to operations as incurred because the underlying technology associated with these expenditures relates to our research and development efforts and has no alternative future uses.

At any time, we have several ongoing research projects. Our internal research and development resources are not directly tied to any individual research project and are primarily deployed across our Contrave and Empatic programs, both of which target the obesity market. We are developing our two obesity product candidates in parallel and, due to the fact that we use shared resources across projects, we do not maintain information regarding our internal costs incurred for our research and development programs on a program-specific basis. We use external service providers to manage our clinical trials, to manufacture the product supplies used in these trials and for formulations development, consulting and other activities.

The following table summarizes our research and development expenses for the three and nine months ended September 30, 2009 and 2008. Costs that are not attributable to a specific research program are included in the "Other" category (in thousands):

                                              Three Months Ended        Nine Months Ended
                                                 September 30,            September 30,
                                              2009           2008       2009          2008
  Costs of external service providers:
  Obesity                                   $   6,958      $ 17,315   $ 30,813      $ 52,217
  Non-Obesity                                    (148 )       1,775       (149 )       3,214
  Other                                            69            83        218           321

  Subtotal                                      6,879        19,173     30,882        55,752
  Internal costs                                1,939         1,657      5,582         4,184
  Stock-based compensation                        774           633      2,115         1,799

  Total research and development expenses   $   9,592      $ 21,463   $ 38,579      $ 61,735

At this time, due to the risks inherent in the clinical trial process and given the stage of our product development programs, we are unable to estimate with any certainty the costs we will incur in the continued development of our product candidates for potential commercialization. Clinical development timelines, the probability of success and development costs can differ materially from expectations. While we are currently focused on advancing each of our product development programs, our future research and development expenses will depend on the clinical success of each product candidate, as well as ongoing assessments as to each product candidate's commercial potential. In addition, we cannot forecast with any degree of certainty which product candidates will be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

We expect our development expenses to decline in the remainder of 2009 due to the completion of our Contrave Phase 3 program, as well as the completion of our latest Phase 2b trial for Empatic. Future development expenses will depend on whether we must conduct additional clinical trials for Contrave, our financial resources, as well as decisions made with respect to our Empatic program. We disclosed the data for the remaining three Contrave Phase 3 trials in July 2009. We disclosed data for our latest Empatic Phase 2b trial in September 2009. The lengthy process of completing our clinical trials and seeking regulatory approval for our product candidates requires the expenditure of substantial resources. Any failure by us or delay in completing our clinical trials, or in obtaining regulatory approvals, could cause a delay in the commencement of product revenues and cause our research and development expenses to increase and, in turn, have a material adverse effect on our results of operations. We do not expect any of our current product candidates to be commercially available in major markets before 2011, if at all.

General and Administrative

Our general and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, accounting and internal support functions. In addition, general and administrative expenses include professional fees for legal, consulting and accounting services. We anticipate increases in general and administrative expenses as we add personnel, comply with the reporting obligations applicable to publicly-held companies, and continue to build our corporate infrastructure in support of our continued development and preparation for the potential commercialization of our product candidates.

Other Income (Expense)

Other income consists of interest earned on our cash, cash equivalents and investment securities. Interest expense generally consists of interest incurred in connection with the $25.0 million credit and security agreement, as amended, with GE Healthcare Financial Services.

Income Taxes

As of December 31, 2008, we had federal and state net operating loss carryforwards of approximately $172.5 million and $175.3 million, respectively. If not utilized, the net operating loss carryforwards will begin expiring in 2022 for federal purposes and 2012 for state purposes. As of December 31, 2008, we had federal and state research and development tax credit carryforwards of approximately $10.4 million and $7.9 million, respectively. The federal tax credits will begin expiring in 2023 unless previously utilized and the state tax credits carry forward indefinitely. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, substantial changes in our ownership may limit the amount of net operating loss carryforwards that could be utilized annually in the future to offset taxable income. An analysis was performed which indicated that multiple ownership changes have occurred in previous years which created annual limitations on our ability to utilize our net operating loss and tax credit carryovers. Such limitations will result in approximately $900,000 of tax benefits related to net operating loss and tax credit carryforwards that will expire unused. Accordingly, the related net operating loss and research and development tax credit carryforwards have been removed from deferred tax assets accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact our effective tax rate as long as we have a full valuation allowance on our deferred tax assets.

Critical Accounting Policies and Estimates

Management's discussion and analysis of our financial condition and results of operations are based upon our financial statements, which are prepared in accordance with accounting principles that are generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. We continually evaluate our estimates and judgments, the most critical of which are those related to accounting for research and development expenses and stock-based compensation costs. We base our estimates and judgments on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known.

There were no significant changes during the nine months ended September 30, 2009 to the items that we disclosed as our critical accounting policies and estimates in Note 2 to our audited financial statements in our Annual Report on Form 10-K for the year ended December 31, 2008.

Results of Operations

Comparison of three months ended September 30, 2009 to three months ended September 30, 2008

Revenues. Revenues for each of the three months ended September 30, 2009 and September 30, 2008 were $22,000 and were related to our sublicensed technology to Cypress.

Research and Development Expenses. Research and development expenses decreased to $9.6 million for the three months ended September 30, 2009 from $21.5 million for the comparable period during 2008. This decrease of approximately $11.9 million was due primarily to a decrease in expenses in connection with our Contrave Phase 3 clinical trials, related proprietary product formulation work and consulting activities totaling approximately $12.9 million. The decrease in research and development expenses was partly offset by an increase in costs incurred in connection with the preparation for our NDA for Contrave of $600,000 and an increase in salaries and personnel related costs totaling approximately $345,000.

General and Administrative Expenses. General and administrative expenses increased to $4.6 million for the three months ended September 30, 2009 from $3.6 million for the comparable period during 2008. This increase of approximately $954,000 was due

primarily to an increase in salaries and personnel related costs of approximately $581,000, an increase in legal and accounting fees of $226,000, an increase in recruiting expense of $150,000, an increase in facilities expenses of $89,000 and an increase in public relations costs of $83,000. The increase in general and administrative expenses was partly offset by a decrease in stock-based compensation expense of approximately $200,000.

Interest Income. Interest income decreased to $47,000 for the three months ended September 30, 2009 from $662,000 for the comparable period during 2008. This decrease of $615,000 was due to lower interest rates.

Interest Expense. Interest expense decreased to $318,000 for the three months ended September 30, 2009 from $370,000 for the comparable period during 2008 due to a lower average interest rate on the amounts outstanding under the credit and security agreement with GE Healthcare Financial Services.

Comparison of nine months ended September 30, 2009 to nine months ended September 30, 2008

Revenues. Revenues for each of the nine month periods ended September 30, 2009 and September 30, 2008 were $66,000 and were related to our sublicensed technology to Cypress.

Research and Development Expenses. Research and development expenses decreased to $38.6 million for the nine months ended September 30, 2009 from $61.7 million for the comparable period during 2008. This decrease of $23.1 million was due primarily to a decrease in expenses in connection with our Contrave Phase 3 clinical trials, related proprietary product formulation work and consulting activities totaling $28.7 million. The decrease in research and development expenses was partly offset by an increase in license fees of $2.5 million, an increase in salaries and personnel related costs totaling approximately $1.4 million and an increase in costs incurred in connection with the preparation for our NDA for Contrave of $1.4 million.

General and Administrative Expenses. General and administrative expenses increased to approximately $12.3 million for the nine months ended September 30, 2009 from approximately $11.0 million for the comparable period during 2008. This increase of approximately $1.3 million was due primarily to an increase in salaries and personnel related costs of approximately $1.3 million, an increase in recruiting expense of $387,000, an increase in public relations costs of $212,000, an increase in facilities expenses of $181,000, and an increase in depreciation expense of $113,000. The increase in general and administrative expenses was partly offset by a decrease in stock-based compensation expense of approximately $687,000 and a decrease in legal and accounting fees of approximately $252,000.

Interest Income. Interest income decreased to $295,000 for the nine months ended September 30, 2009 from $2.8 million for the comparable period during 2008. This decrease of approximately $2.5 million was due to lower interest rates and a decrease in average cash and investment balances.

Interest Expense. Interest expense decreased to $1.1 million for the nine months ended September 30, 2009 from $1.2 million for the comparable period during 2008. This decrease of approximately $126,000 was primarily due to the decrease in interest expense resulting from a lower average interest rate on the $23.8 million borrowed under the credit and security agreement with GE Healthcare Financial Services as of September 30, 2009.

Liquidity and Capital Resources

Since inception, our operations have been financed primarily through the sale of equity securities. Through September 30, 2009, we received net proceeds of approximately $320.2 million from the sale of shares of our preferred and common stock as follows:

• from September 12, 2002 to December 31, 2006, we issued and sold a total of 1,053,572 shares of common stock for aggregate net proceeds of $14,801;

• in March 2004, we issued and sold a total of 9,322,035 shares of Series A redeemable convertible preferred stock for aggregate net proceeds of $9.2 million and the conversion of promissory notes and interest thereon totaling $1.7 million;

• from April 2005 to May 2005, we issued and sold 14,830,509 shares of Series B redeemable convertible preferred stock for aggregate net proceeds of $34.9 million;

• in November 2006, we issued and sold a total of 8,771,930 shares of Series C convertible preferred stock for aggregate net proceeds of $29.9 million;

• in January and February 2008, we issued and sold a total of 7,326,435 shares of common stock for aggregate net proceeds of $74.9 million; and

• in July 2009, we issued and sold a total of 11,500,000 million shares of common stock for aggregate net proceeds of $81.6 million.

As of September 30, 2009, we had $56.9 million in cash and cash equivalents and an additional $50.9 million in investment securities, available-for-sale. As of September 30, 2009, our holdings primarily consisted of treasury-backed money market funds, treasuries, other instruments that are insured, guaranteed or supported by the U.S. federal government, and corporate debt obligations. We maintain established guidelines relating to diversification and maturities of our investments to preserve principal and maintain liquidity.

Net cash used in operating activities was $54.8 million and $56.9 million for the nine months ended September 30, 2009 and 2008, respectively. Net cash used in each of these periods was primarily a result of external research and development expenses, clinical trial costs, personnel-related costs, third-party supplier expenses and professional fees.

Net cash used in investing activities was $10.7 million for the nine months ended September 30, 2009 and the net cash provided by investing activities was $8.6 million for the nine months ended September 30, 2008. These amounts are primarily the result of the net purchases and maturities of investment securities.

Net cash provided by financing activities was $76.9 million and $71.9 million for the nine months ended September 30, 2009 and 2008, respectively. The net cash provided by financing activities for the nine months ended September 30, 2009 was a result of the public sale of common stock in July 2009 for aggregate net proceeds of $81.6 million, and was partially offset by payments of principal towards our credit and security agreement with GE Healthcare Financial Services, as amended. The net cash provided by financing activities for the nine months ended September 30, 2008 is primarily as a result of the public sale of common stock in January and February 2008 for aggregate net proceeds of $74.9 million.

We cannot be certain if, when or to what extent we will receive cash inflows from the commercialization of our product candidates. We expect our pre-commercialization and commercialization expenses to be substantial and to increase over the next few years as we seek approval for and launch Contrave, and we expect development expenses will increase as we continue the advancement of Empatic.

We have entered into license agreements to acquire the rights to develop and commercialize Contrave and Empatic. Pursuant to these agreements, we obtained exclusive and non-exclusive licenses to the patent rights and know-how for selected indications and territories. Under our license agreement with Duke University, we issued 442,624 shares of our common stock in March 2004 and may be required to make future milestone payments totaling up to $1.7 million upon the achievement of various milestones related to regulatory or commercial events. Under our license agreement with Lee Dante, M.D., we issued an option to purchase 73,448 shares of our common stock in April 2004 at an exercise price of $0.10 per share, which expires in April 2014. We also paid Dr. Dante an upfront fee of $100,000 and may be required to make future milestone payments totaling up to $1.0 million upon the achievement of a milestone related to a regulatory event. Under our license agreement with Oregon Health & Science University, we issued 76,315 shares of our common stock in December 2003 and paid an upfront fee of $65,000. Under these three agreements, we are also obligated to pay royalties on any net sales of the licensed products. Under our license agreement with SmithKline Beecham Corporation and Glaxo Group Limited, we paid an upfront payment and may be required to make a future milestone payment upon the earliest achievement of certain milestones primarily relating to regulatory or commercial events.

Our future capital uses and requirements depend on numerous factors. These factors include but are not limited to the following:

• the rate of progress and cost of our clinical trials and other product development programs for Contrave, to the extent additional clinical trials need to be conducted, and Empatic, including expenses to support the trials and milestone payments that may become payable;

• our ability to establish and maintain strategic collaborations, including licensing and other arrangements;

• the costs and timing of regulatory approvals;

• the costs of establishing sales or distribution capabilities;

• the successful commercialization of our products; and

• the extent to which we in-license, acquire or invest in other indications, products, technologies and businesses.

In December 2006, we entered into a credit and security agreement with Merrill Lynch Capital providing for potential borrowing until June 30, 2007 of up to $17.0 million. In July 2007, we entered into a first amendment to the credit and security agreement with Merrill Lynch Capital. The first amendment provided for, among other things, the extension of the period during which Merrill Lynch Capital was obligated to make advances under the credit and security agreement to us from June 30, 2007 to December 31, 2007. In November 2007, we entered into a second amendment to the credit and security agreement with Merrill Lynch Capital. The second amendment provided for, among other things, the increase of the total amount available for advances under the credit and security agreement from $17.0 million to $25.0 million, our obligation to request an advance of $8.0 million on or before December 31, 2007, and the extension of the period during which Merrill Lynch Capital is obligated to make advances to us under the credit and security agreement from December 31, 2007 to December 31, 2008. GE Healthcare Financial Services acquired a portfolio of loans from Merrill Lynch Capital in 2008, and the credit and security agreement, as amended, was subsequently assigned to GE Healthcare Financial Services.

We drew down $10.0 million, $8.0 million and $5.8 million under the credit and security agreement in March 2007, December 2007 and December 2008, respectively. Under the credit and security agreement, we are required to make monthly payments of principal and interest and all amounts then outstanding will become due and payable upon the earlier to occur of July 1, 2011 or three years from the funding of any amounts under the agreement. Interest accrues on amounts outstanding under the agreement at a base rate set forth in the agreement plus an applicable margin, which ranges from 3.75% to 4.25% based on the date of borrowing. Amounts outstanding under the credit and security agreement at September 30, 2009 bear interest at an average rate of 7.4%. The loan is collateralized by substantially all of our assets other than, subject to certain limited exceptions, intellectual property. Subject to certain limited exceptions, amounts prepaid under the credit and security agreement are subject to a prepayment fee equal to 3% of the amount prepaid. In addition, upon repayment of the amounts borrowed for any reason, we will be required to pay an exit fee of approximately $1.2 million. Under the terms of the agreement, we are subject to operational covenants, including limitations on our ability to incur liens or additional debt, pay dividends, redeem our stock, make specified investments and engage in merger, consolidation or asset sale transactions, among other restrictions.

We believe that our existing cash and cash equivalents will be sufficient to meet our projected operating requirements through at least the next 12 months.

Until we can generate significant cash from our operations, we expect to continue to fund our operations with existing cash resources, proceeds of potential offerings of our equity securities, potential borrowings and potential corporate collaborations. In addition, we may finance future cash needs through the sale of additional equity securities, strategic collaboration agreements and other debt financing. In addition, we cannot be sure that our existing cash and investment resources will be adequate, that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or our stockholders. Having insufficient funds may require us to delay, scale back or eliminate some or all of our development programs, relinquish some or even all rights to product candidates or renegotiate less . . .